[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 2,975,063 ordinary shares of each under the second tranche of its buyback programme announced 31 July 2025. The trades were executed on 26-27 August 2025 on the London Stock Exchange CBOE (UK)/CXE with individual trade prices reported and a weighted figure of 359.1984 shown in the announcement. After settlement the company's registered share capital is 8,966,351,142 ordinary shares of each, of which 3,880,205 are held as treasury shares, leaving 8,962,470,937 ordinary shares with voting rights. The announcement directs readers to a full trade breakdown and to the company's investor website for details.

Positive

• Completed share buyback tranche: 2,975,063 ordinary shares purchased and cancelled under the programme
• Regulatory compliance: Full trade breakdown provided and voting share count updated for FCA disclosure thresholds
• Clear post-transaction share counts: Registered share capital reported as 8,966,351,142; voting shares 8,962,470,937

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine tranche of share buyback completed; small reduction in shares outstanding with detailed trade breakdown provided.

The company executed a buyback of 2,975,063 ordinary shares under its second tranche. The filing provides execution dates (26-27 August 2025), exchange venue and a weighted trade figure of 359.1984. Post-settlement share counts are given, showing 8,966,351,142 registered shares and 8,962,470,937 voting shares after treasury holdings of 3,880,205. The disclosure follows market abuse regulation requirements by linking to a full trade breakdown. Given the absolute size of the purchase relative to total shares outstanding, the transaction appears operationally routine rather than transformational.

Corporate Governance Expert

TL;DR: Disclosure complies with regulatory rules and updates voting share count for shareholder notification thresholds.

The Form 6-K supplies the necessary regulatory disclosure: number of shares purchased and cancelled, post-transaction registered capital, treasury holdings and the resulting voting shares figure. The announcement explicitly notes the voting shares figure may be used for FCA notification thresholds and provides a link to a full trade breakdown in accordance with the Market Abuse Regulation. This meets standard transparency expectations for buyback programmes.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	27 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

27 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,975,063 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	26 August 2025	26 August 2025	26 August 2025
Number of Shares purchased:	2,975,063	-	-
Highest price paid per Share (p):	363.3000	-	-
Lowest price paid per Share (p):	355.6000	-	-
Volume weighted average price paid per Share (p):	359.1984	-	-

Following the settlement of the above, the Company's registered share capital is 8,966,351,142 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,962,470,937 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7550W_1-2025-8-26.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 27, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon plc (HLN) purchase in this tranche?

Haleon purchased and cancelled 2,975,063 ordinary shares under the second tranche of its buyback programme.

What are Haleon's post-transaction share counts?

The company's registered share capital is 8,966,351,142 ordinary shares; 3,880,205 are held as treasury shares, leaving 8,962,470,937 ordinary shares with voting rights.

When and where were the trades executed?

Trades were executed on 26-27 August 2025 on the London Stock Exchange CBOE (UK)/CXE, with a weighted trade figure shown as 359.1984 in the announcement.

Where can I find the full breakdown of individual trades?

The announcement links to a full trade breakdown at http://www.rns-pdf.londonstockexchange.com/rns/7550W_1-2025-8-26.pdf and to the company's investor website at www.haleon.com/investors.

Does this announcement affect shareholder notification thresholds?

Yes. The filing states the updated voting share figure (8,962,470,937) may be used by shareholders to determine if they must notify changes under the FCA's Disclosure Guidance and Transparency Rules.